Two ME/CFS, yes, ME/CFS low dose naltrexone papers appear, one fibromyalgia report attempts to turn dosing protocols on their head, one patient blows through normal dose levels with spectacular success, Jarred Younger hunts for a more powerful naltrexone, and then...
Something extraordinary happened to me last weekend. Following three horrid nights of sleep, I spent 13 hours a day for the next three days in a room with 135 people – and emerged in much better condition than when I had started. That I would not have predicted....
In the third of a series of interviews since full-time ME/CFS advocate Emily Taylor joined Solve ME, I talked to her about what the heck is going with advocacy. I learned a lot. In particular, I learned there’s a lot going on that I didn’t know about....
It must have seemed like a done deal. Daiichi Sankyo was so confident that its safer, more effective version of Lyrica (pregabalin) called Mirogabalin was going to beat the pants off the best-selling drug for FM. How confident were they? They funded easily the largest...
Leonard Jason and Ben Katz have been concerned that pediatric patients (generally assumed to be from 0-18 years of age) have been given short shrift for awhile. In their 2012 article, “Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome”, they...
Keep the information flowing! Support Health Rising during our end of the year fundraising drive. Click here for more.
Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News
Get Health Rising's free blogs featuring the latest findings and treatment options for the ME/CFS, long COVID, fibromyalgia and complex chronic disease communities.